Eli Lilly sues HHS to halt any 340B-related monetary penalties
The Biden administration’s fight with drugmakers over a drug discount program, known as 340B, is starting to boil over.
Just days after HHS set a June 1 deadline for biopharma companies to get in line with the department’s views on the 340B statute and allow hospitals’ contract pharmacies to gain access to deeply discounted drugs or pay steep fines, Eli Lilly late Thursday filed a motion in an Indiana district court to stop HHS in its tracks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.